HIV cure may lie in radioimmunotherapy

Date: Dec-05-2013A new study suggests targeting HIV with radioimmunotherapy could eradicate HIV from infected

cells. If given in conjunction with highly active antiretroviral therapy, it may form the basis of a

cure.

Although highly active antiretroviral therapy (HAART) kills human immunodeficiency virus (HIV) in the bloodstream, it does not completely eliminate

it from the body because the virus can linger in infected cells and replicate.

Researchers from the Albert Einstein College of Medicine of Yeshiva University in New York presented their

findings at the 99th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA)

in Chicago, IL, this week.

Study leader Ekaterina Dadachova, professor of radiology and of microbiology & immunology, says although

there has been enormous progress in HIV treatments that slow progression to AIDS, the search for a permanent

cure continues. She explains:

"To combat HIV, we need a method that will completely eliminate all HIV-infected cells without damaging

non-infected cells."

In radioimmunotherapy (RIT), which has been used for a while to treat cancer, antibodies charged with

radioactive isotopes target and destroy cancer cells.

The antibody selects the particular type of cancer cell and the attached radioisotope delivers a lethal dose

of radiation that kills the target cell, while leaving untargeted (healthy) cells unharmed.
HIV infection reduced to undetectable levels

In previous work, Prof. Dadachova had already managed to use the approach in the lab to target and destroy

human immune cells infected with HIV.

At the meeting, she and her colleagues presented the results of a study in which they used the approach to

treat blood samples from people infected with HIV.

The blood samples came from 15 HIV patients receiving HAART treatment at the AIDS Center at Montefiore,

the University Hospital for Einstein College and academic medical center.

The results showed that RIT targeted and killed HAART-treated lymphocytes - types of white blood cells - and

in most samples, reduced HIV infection to undetectable levels.

The team then went on to see if RIT could reach HIV-infected cells in the brain and central nervous

system.

This would be a big step because current antiretrovirals do not cross the blood-brain barrier very well,

which is why so many HIV patients treated with HAART often have severe mental impairment.

For this test, they used a lab model of the blood-brain barrier made with human cells and discovered that the

same radioisotope-charged antibodies used in earlier experiments could destroy HIV-infected cells in the brain

without damaging the barrier.

Prof. Dadachova says:

"We found that radioimmunotherapy could kill HIV-infected cells both in blood samples that received

antiretroviral treatment and within the central nervous system, demonstrating RIT offers real potential for

being developed into an HIV cure."

In another study published recently in the Journal of Infectious Diseases, researchers from Lund

University in Sweden describe how they found that an aggressive new HIV strain leads to AIDS more quickly than

other current strains.

Written by Catharine Paddock PhD

Copyright: Medical News Today

Not to be reproduced without the permission of Medical News Today.

Courtesy: Medical News Today Note: Any medical information available in this news section is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional.